How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,365 results for

adhd Cognitive behavioural therapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. (Abstract)

Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Attention deficit hyperactivity disorder (ADHD) in children is associated with hyperactivity and impulsivity, attention problems, and difficulties with social interactions. Pharmacological treatment may alleviate the symptoms of ADHD but this rarely solves difficulties with social interactions. Children with ADHD may benefit from interventions designed to improve their social skills. We (...) comorbidities.The social skills interventions were described as: 1) social skills training, 2) cognitive behavioural therapy, 3) multimodal behavioural/psychosocial therapy, 4) child life and attention skills treatment, 5) life skills training, 6) the "challenging horizon programme", 7) verbal self-instruction, 8) meta-cognitive training, 9) behavioural therapy, 10) behavioural and social skills treatment, and 11) psychosocial treatment. The control interventions were no intervention or waiting list.The

2019 Cochrane

2. Attention deficit hyperactivity disorder: diagnosis and management

(see recommendation 1.5.4) Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 62a baseline assessment has been carried out (see recommendation 1.7.4). See the recommendations on medication. [2018] [2018] 1.5.14 Consider a course of cognitive behavioural therapy (CBT) for young people with ADHD who have benefited from medication but whose (...) on individual strengths improving access to services Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 12 of 62the negative impacts of receiving a diagnosis, such as stigma and labelling a greater tendency for impulsive behaviour the importance of environmental modifications to reduce the impact of ADHD symptoms education issues (for example, reasonable

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Attention deficit hyperactivity disorder in adults

disorders are not active. Treat obvious psychiatric disorders as normal and assess the effects of that treatment on cognition (attention, concentration, memory) carefully. Stimulant medications (methylphenidate, amfetamine derivatives) are first-line treatment and non-stimulant medications, including atomoxetine, form second-line management. Psychological therapies including cognitive behaviour therapy, metacognitive therapy, and dialectic behaviour therapy can be effective in reduction of symptoms (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

4. Attention deficit hyperactivity disorder in adults

disorders are not active. Treat obvious psychiatric disorders as normal and assess the effects of that treatment on cognition (attention, concentration, memory) carefully. Stimulant medications (methylphenidate, amfetamine derivatives) are first-line treatment and non-stimulant medications, including atomoxetine, form second-line management. Psychological therapies including cognitive behaviour therapy, metacognitive therapy, and dialectic behaviour therapy can be effective in reduction of symptoms (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

5. Effectiveness of Parents-Focused Cognitive-Behavioral Therapy on Attention Deficit Hyperactivity Disorder Symptoms, Obesity and Self-Esteem of Overweight Children with Attention Deficient Hyperactivity Disorder Full Text available with Trip Pro

Effectiveness of Parents-Focused Cognitive-Behavioral Therapy on Attention Deficit Hyperactivity Disorder Symptoms, Obesity and Self-Esteem of Overweight Children with Attention Deficient Hyperactivity Disorder Attention deficit hyperactivity disorder (ADHD) is the most common behavioral problems that cause hyperactivity, attention deficits, academic failure, and emotional and behavioral problems in preschool and elementary school that is often hidden from the parents' eyes. The aim (...) of this study was to determine the effectiveness of parent-based cognitive-behavioral therapy (CBT) on ADHD symptoms (including attention deficit disorder, restlessness, and impulsivity), overweight and self-esteem of 6-11-year-old obese children with attention deficit hyperactivity in Isfahan.This quasi-experimental study was carried out on 40 children aged 6-11 years with ADHD and overweight or obesity (above the 85th percentile in weight for age, height, and sex diagram) that their parents referred

2018 Advanced biomedical research Controlled trial quality: uncertain

6. Self-Management Intervention for Attention and Executive Functions Using Equine-Assisted Occupational Therapy Among Children Aged 6-14 Diagnosed with Attention Deficit/Hyperactivity Disorder. (Abstract)

Self-Management Intervention for Attention and Executive Functions Using Equine-Assisted Occupational Therapy Among Children Aged 6-14 Diagnosed with Attention Deficit/Hyperactivity Disorder. Background: Attention deficit/hyperactivity disorder (ADHD), characterized by inattention, hyperactivity, and impulsivity, is currently one of the most common diagnoses given to children. Children with ADHD have a unique cognitive profile that involves difficulties in executive functions (EFs (...) ) and in the self-management system of the brain, and are at higher risk for educational failure, social and emotional difficulties, and high risk behavior. Objectives: The purpose of this study was to examine the effectiveness of self-management intervention for attention and executive functions using equine-assisted occupational therapy (STABLE-OT) for school-aged children with ADHD. Design: A pre-post design was used in the intervention. Setting/location: The study was conducted at two riding school stables

2020 Journal of Alternative and Complementary Medicine

7. A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial. Full Text available with Trip Pro

A Comparison of Cognitive-Behavioral Therapy and Pharmacotherapy vs. Pharmacotherapy Alone in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)-A Randomized Controlled Trial. In the treatment of adult attention-deficit/hyperactivity disorder (ADHD) the importance of psychological interventions in combination with pharmacotherapy is widely accepted in contemporary clinical routine. The natural course of the disorder seems to justify additional psychological interventions because even (...) conditions was done. Afterwards both groups underwent treatment for about 10-12 weeks, the experimental group receiving sessions of cognitive-behavioral therapy (CBT) whereas the control group only received medication and standard clinical management (SCM). ADHD symptoms differed statistically during time but not between the two different treatment conditions. This result was the same for the single ADHD symptoms-inattention, hyperactivity, impulsivity, and emotional symptoms-and also for impairment

2018 Frontiers in Psychiatry Controlled trial quality: uncertain

8. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents

for relevant articles from completed studies. Gray literature databases included ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform search portal, and the National Guidelines Clearinghouse. As an additional step in identifying adverse effects of interest, we reviewed the known adverse effects of attention deficit hyperactivity disorder (ADHD) medications monitored by the Food and Drug Administration (FDA). 80 As a result of that assessment, we added two (...) since the original 2011 report was available on ADHD medications approved by the Food and Drug Administration (FDA) compared with placebo or compared to different FDA-approved ADHD medications (SOE=insufficient). For atomoxetine and methylphenidate, the most commonly reported adverse events were somnolence and mild gastrointestinal problems. Atomoxetine had slightly higher gastrointestinal effects than methylphenidate (SOE=low). Cognitive behavioral therapy improved ADHD symptoms (SOE=low). Child

2018 Effective Health Care Program (AHRQ)

9. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. (Abstract)

Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. This study aimed to investigate the efficacy of docosahexaenoic acid (DHA) dietary supplementation on behavior and cognition in school-aged, drug-naïve children with attention-deficit/hyperactivity disorder (ADHD). A total of 50 participants with ADHD aged 7 to 14 were enrolled in a 6-month randomized, placebo-controlled (...) appears to have small positive effects on other behavioral and cognitive difficulties, which, in light of the absence of side-effects, could be reasonably followed up in future intervention studies. ( https://clinicaltrials.gov/ct2/show/NCT01796262 : The Effects of DHA on Attention Deficit and Hyperactivity Disorder (DADA)).

2018 European child & adolescent psychiatry Controlled trial quality: predicted high

10. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attention deficit hyperactivity disorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD (...) with ADHD should always form part of a comprehensive treatment plan that includes psychological, behavioural and educational advice and interventions. Where drug treatment is considered appropriate, the guideline recommends methylphenidate, atomoxetine and dexamfetamine, within their licensed indications, as options for the management of ADHD in children and young people. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70) © NICE 2018. All rights

2016 National Institute for Health and Clinical Excellence - Advice

11. Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder

Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) disorder Article Text Psychological interventions Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder David Coghill Statistics from Altmetric.com ABSTRACT FROM : Vidal R, Castells J, Richarte V, et al . Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54:275–82. What is already known on this topic Persistence of attention

2015 Evidence-Based Mental Health

12. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (Abstract)

Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine (...) dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition.Twenty-five adults with ADHD were scanned twice with event-related functional magnetic resonance imaging while performing an emotional go/no-go task after 3 to 4 weeks of lisdexamfetamine treatment and 3 weeks off medication in a randomized, counterbalanced, hybrid crossover design. Drug, trial type, and face emotion (happy, sad, or neutral) were included as within-subjects factors

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

13. Cognitive-Behavioral Therapy for Children With Anxiety and Comorbid Attention-Deficit/Hyperactivity Disorder. (Abstract)

Cognitive-Behavioral Therapy for Children With Anxiety and Comorbid Attention-Deficit/Hyperactivity Disorder. To determine whether comorbid attention-deficit/hyperactivity disorder (ADHD) diagnosis (including subtype) predicts response to cognitive-behavior therapy (CBT) for anxiety in children and to examine change in ADHD symptoms after treatment of primary anxiety.A sample of 842 children 5 to 18 years of age received CBT for a primary anxiety disorder. A subsample of 94 children met (...) criteria for comorbid mild-to-moderate ADHD, mostly consisting of predominantly inattentive (n = 61) and combined (n = 27) subtypes. Outcome was defined as response (change in diagnostic severity) and remission (absence of the primary diagnosis) at each time point (after treatment and 3- and/or 6-month follow-up) and analyzed using linear and logistic mixed models.Neither ADHD diagnosis nor subtype predicted response or remission rates for children's primary anxiety disorders. Children with ADHD also

2018 Journal of the American Academy of Child and Adolescent Psychiatry

14. Treating a Child With Anxiety and Attention-Deficit/Hyperactivity Disorder? Don't Rule Out Cognitive-Behavioral Therapy. (Abstract)

Treating a Child With Anxiety and Attention-Deficit/Hyperactivity Disorder? Don't Rule Out Cognitive-Behavioral Therapy. Anxiety disorders (ADs) and attention deficit/hyperactivity disorder (ADHD) are two of the most common psychiatric disorders in youth and approximately 25% of those with an AD have comorbid ADHD.1 Children with AD and ADHD evidence greater impairment than those with either disorder alone, making them a particularly vulnerable population in need of effective treatment.2 (...) Although a strong evidence base supports the efficacy of cognitive-behavioral therapy (CBT) for treating anxiety in children,3 there is little information to guide practitioners on how to best treat those dually diagnosed with an AD and ADHD. Questions have arisen as to whether the cognitive, attentional, and behavioral impairments associated with ADHD interfere with the ability of these children to benefit from CBT for anxiety.4 Does the distractibility and overactivity characteristic of ADHD inhibit

2018 Journal of the American Academy of Child and Adolescent Psychiatry

15. Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults)

Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults) Cognitive Behavioral Therapy for adult ADHD – Society of Clinical Psychology Description Cognitive behavioral therapy (CBT) for adult ADHD provides concrete strategies and skills for coping with the core symptoms of ADHD (inattention, hyperactivity, impulsivity) and associated impairment in social, occupational, educational, and other domains. Components of CBT for ADHD include psychoeducation, training (...) ., Winett, C.L., Wilens, T.E., & Biederman, J. (2005). Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behaviour Research and Therapy, 43 , 831-842. Clinical Resources Safren SA, Perlman CA, Sprich S, Otto MW. Mastering Your Adult ADHD: A Cognitive-Behavioral Therapy Approach. New York, NY: Oxford University Press; 2005. Safren SA, Sprich S, Perlman CA, Otto MW. Mastering Your Adult ADHD: A Cognitive-Behavioral Treatment Program Client Workbook. New York, NY

2014 Society of Clinical Psychology

16. Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation. Full Text available with Trip Pro

Effects and clinical feasibility of a behavioral treatment for sleep problems in adult attention deficit hyperactivity disorder (ADHD): a pragmatic within-group pilot evaluation. Sleep disturbances, including insomnia, are common in adult Attention Deficit Hyperactivity Disorder (ADHD). Treatment of choice for insomnia is cognitive behavioral therapy (CBT-i), but evidence is lacking for CBT-i in patients with ADHD. The purpose of this study was to investigate if patients with insomnia and other (...) sleep problems, at a specialist clinic for ADHD, benefit from a group delivered behavioral treatment based on CBT-i; whether insomnia severity improves following this treatment.This pragmatic within-group pilot study with a pre to post and three-month follow-up design was set at a specialist psychiatric out-patient clinic for adult ADHD. As an adjunct to care-as-usual at the clinic, a CBT-i-based group treatment targeting several sleep problems prevalent in the ADHD-population, was offered as 10

2019 BMC Psychiatry

17. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin

in the UK. No robust evidence was identified indicating that melatonin-related improvement in sleep onset or sleep onset latency led to a subsequent improvement in daytime ADHD behaviour, cognition or quality of life. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 25T T able 1 Summary of the trials able 1 (...) -line treatments for children with sleep problems and ADHD include ensuring good sleep hygiene and behavioural therapy [11] . It has been suggested that in some patients sleep disturbances may be related to pre-existing ADHD symptoms that could respond to dose adjustment or switching to a stimulant agent associated with fewer sleep difficulties [11] . Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2) © NICE 2018. All rights reserved

2013 National Institute for Health and Clinical Excellence - Advice

18. Brain-behavior patterns define a dimensional biotype in medication-naïve adults with attention-deficit hyperactivity disorder. Full Text available with Trip Pro

Brain-behavior patterns define a dimensional biotype in medication-naïve adults with attention-deficit hyperactivity disorder. Childhood-onset attention-deficit hyperactivity disorder (ADHD) in adults is clinically heterogeneous and commonly presents with different patterns of cognitive deficits. It is unclear if this clinical heterogeneity expresses a dimensional or categorical difference in ADHD.We first studied differences in functional connectivity in multi-echo resting-state functional (...) biotypes of adult ADHD.Overall, our data advance a novel finding that the reduced functional segregation between default-mode and cognitive control networks supports a clinically important dimensional biotype of childhood-onset adult ADHD. Despite the heterogeneity of its presentation, our work suggests that childhood-onset adult ADHD is a single disorder characterized by dimensional brain-symptom mediators.

2018 Psychological Medicine

19. High Dose Stimulants for Attention Deficit Hyperactivity Disorder

Adolesc Psychopharmacol. 2010 Feb;20(1):49-54. PubMed: PM20166796 High Dose Stimulants for ADHD 4 Adults 8. Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open- label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011 Feb;31(1):108-14. PubMed: PM21192153 Guidelines and Recommendations No literature identified. PREPARED BY: Canadian Agency for Drugs and Technologies (...) Hyperactivity Disorder: Clinical Effectiveness, Safety, and Guidelines DATE: 29 January 2015 RESEARCH QUESTIONS 1. What is the effectiveness and safety of high dose stimulants in children and adolescents (six to18 years) with attention deficit hyperactivity disorder (ADHD)? 2. What is the comparative effectiveness and safety of high dose stimulants in adults (>18 years) with ADHD? 3. What are the evidence-based guidelines regarding the use of high dose stimulants in patients with ADHD? KEY FINDINGS One

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

Posted: May 24, 2018 Last Verified: May 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior (...) additive effects in improving attention in adults. However, the specific actions of these substances have not been examined in children and adolescents with attention deficit hyperactivity disorder (ADHD), who are characterized by impaired attention, hyperkinesia and impulsivity. Therefore, the investigators plan to study the functional activity of brains (both at rest and when performing standard tasks designed to measure attention) in children diagnosed with ADHD using functional magnetic resonance

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>